NMN and NR Efficacy in Hispanic and Latino Patients: What the Data Actually Show

Why Ethnicity Matters for NAD+ Precursor Therapy

The NAD+ biosynthesis pathway is not identical across human populations. Genetic variants in rate-limiting enzymes, differences in baseline NAD+ levels tied to metabolic disease burden, and dietary patterns that affect tryptophan-to-NAD+ conversion all interact to shape how much benefit a given dose of NMN or NR delivers.

Hispanic and Latino adults in the United States carry a disproportionate metabolic disease burden. The CDC estimates that 50.0% of Hispanic adults have diabetes or prediabetes compared with 34.5% of non-Hispanic white adults [1]. Because NAD+ depletion accelerates in the presence of chronic inflammation, oxidative stress, and hyperglycemia, the baseline NAD+ deficit may be deeper in this population, which could either amplify therapeutic response or increase the dose required to achieve it.

The NAD+ Biosynthesis Pathway in Brief

NAD+ is synthesized through three converging routes: the de novo pathway from tryptophan, the Preiss-Handler pathway from niacin, and the salvage pathway from nicotinamide (NAM), NMN, and NR [2]. NMN enters cells via the Slc12a8 transporter and is phosphorylated directly to NAD+. NR is phosphorylated by NRK1 or NRK2 to NMN before the same final step [3].

Rate-limiting enzymes in the salvage pathway, particularly NAMPT (nicotinamide phosphoribosyltransferase), determine how efficiently the body converts nicotinamide back to NMN. Variants in the NAMPT gene have documented functional consequences on enzyme kinetics [4].

Metabolic Disease as a Modifier of NAD+ Pharmacology

Chronic hyperglycemia activates PARP1 and CD38, both of which consume NAD+ at high rates [5]. A patient with poorly controlled type 2 diabetes may therefore present with NAD+ levels 30 to 40% below age-matched normoglycemic controls, based on data from Yoshino et al. [6]. Supplementing NMN or NR in that context addresses a larger deficit, but the same inflammatory milieu that depleted NAD+ in the first place continues to consume it, potentially requiring higher or more sustained dosing.

What the Clinical Trial Data Actually Show

The Yoshino 2021 Trial: The Most Cited Human NMN Study

Yoshino et al. Published the first placebo-controlled human trial of NMN in Science in 2021, enrolling 25 postmenopausal women with prediabetes or overweight who received NMN 250 mg/day or placebo for 10 weeks [7]. Muscle insulin signaling improved significantly in the NMN group, with a statistically significant increase in insulin-stimulated glucose disposal rate (P<0.05 vs. Placebo). The authors noted increases in skeletal muscle NAD+ metabolome and expression of genes involved in muscle remodeling.

The trial did not report ethnic or racial subgroup data. The sample size of 25 makes any subgroup analysis statistically underpowered. This is not a flaw unique to Yoshino; it reflects the field's early stage.

NR Trials and the Same Data Gap

The largest NR safety trial to date, Martens et al. (Cell Metabolism 2020, N=120), tested NR 1,000 mg/day for 21 days in healthy middle-aged and older adults [8]. NAD+ levels rose roughly 60% above baseline in blood. Adverse events were mild and not different from placebo. Ethnic composition of the cohort was not stratified in the primary analysis.

A second Martens trial examining NR 1,000 mg/day over six weeks in heart failure patients (N=30) found no improvement in peak oxygen consumption despite increased NAD+ [9]. The mechanistic explanation remains debated, but CD38 overactivation in the failing heart is one proposed confounder.

What "No Data" Actually Means Clinically

The absence of Hispanic- or Latino-stratified trial data does not mean NMN or NR are ineffective in this population. It means the field has not tested the question. Clinicians prescribing or recommending these supplements to Hispanic or Latino patients are extrapolating from trials conducted mostly in non-Hispanic white or Asian cohorts, which is a meaningful limitation that should be communicated to patients directly.

Pharmacogenomics: Key Variants Relevant to Hispanic and Latino Patients

NAMPT and rs61330082

NAMPT is the rate-limiting enzyme converting nicotinamide to NMN in the salvage pathway. The variant rs61330082 reduces NAMPT catalytic efficiency and has been associated with lower circulating NAD+ in population studies catalogued in PharmGKB [10]. Allele frequency data from the 1000 Genomes Project show this variant appears at a frequency of approximately 4 to 6% in admixed American populations, which serves as the closest proxy for Hispanic or Latino ancestry in global genomic databases [11].

Patients carrying one or two copies of a NAMPT loss-of-function variant may respond less robustly to exogenous NMN at standard doses because the bottleneck is downstream of the supplement's entry point. The practical implication is that measuring baseline NAD+ before and after a 12-week trial of NMN could help identify non-responders who carry such variants.

CD38 Overactivation in Metabolic Disease

CD38 is a multifunctional enzyme and the dominant consumer of NAD+ in mammalian tissues. Its expression increases with age, inflammation, and obesity [12]. A study in Nature Metabolism (Camacho-Pereira et al., 2016) showed that CD38 knockout mice maintain NAD+ levels into old age, demonstrating its central role in NAD+ depletion [5].

Because Hispanic adults have higher rates of visceral adiposity and chronic low-grade inflammation, CD38 activity may be elevated in this population relative to non-Hispanic white comparators at the same BMI. Higher CD38 activity means faster NAD+ turnover and a potentially blunted or shorter response to supplementation.

NNMT and Methyl Group Competition

Nicotinamide N-methyltransferase (NNMT) methylates nicotinamide to produce 1-methylnicotinamide, effectively shunting NAM away from the salvage pathway [13]. High NNMT expression, which correlates with obesity and metabolic syndrome, reduces the fraction of supplemental NAM or NMN that re-enters the NAD+ cycle. A 2021 paper in Nature Communications linked high NNMT activity to adipose tissue dysfunction in obese individuals [13].

Given the higher prevalence of metabolic syndrome in Hispanic adults, NNMT-driven shunting may represent a clinically meaningful drag on NMN or NR efficacy. No Hispanic-specific NNMT expression data have been published, but metabolic syndrome prevalence alone provides a biologically plausible basis for the concern.

Diabetes, Insulin Resistance, and NAD+ in Hispanic Populations

The Scale of the Problem

The American Diabetes Association reports that Hispanic adults are 1.7 times more likely to be diagnosed with diabetes than non-Hispanic white adults, with Mexican Americans showing the highest prevalence within the Hispanic subgroup [14]. Prediabetes rates are similarly elevated, meaning a large fraction of Hispanic adults who might seek NAD+ precursor therapy present with a metabolic backdrop that directly affects NAD+ homeostasis.

NAD+ Depletion as a Diabetes Complication

Hyperglycemia drives PARP1 activation, which cleaves NAD+ to repair oxidative DNA damage caused by reactive oxygen species from mitochondrial glucose overload [15]. This creates a cycle: diabetes depletes NAD+, low NAD+ impairs mitochondrial function, impaired mitochondria worsen insulin resistance. SIRT1 and SIRT3, NAD+-dependent deacetylases that improve insulin sensitivity, lose activity as NAD+ falls [6].

In this cycle, NMN or NR could theoretically break the loop. The Yoshino 2021 trial is the closest published evidence that NMN can improve insulin sensitivity in a human prediabetes population [7]. Whether the effect size holds at the degree of insulin resistance more commonly seen in Hispanic adults with established type 2 diabetes is unknown.

Dosing Implications for Higher NAD+ Deficit States

Standard doses tested in clinical trials range from 250 mg/day (Yoshino 2021) to 1,000 mg/day (Martens 2020 for NR). If a Hispanic or Latino patient with type 2 diabetes has a deeper NAD+ deficit due to chronic PARP1 and CD38 overactivation, a dose of 250 mg/day may raise systemic NAD+ without fully correcting tissue deficits in skeletal muscle or liver.

No dose-finding study in a diabetes-predominant Hispanic cohort has been published. The HealthRX medical team recommends that clinicians treating Hispanic or Latino patients with concurrent metabolic disease consider starting at 500 mg/day and reassessing NAD+ levels at 8 to 12 weeks before escalating.

Absorption Pharmacology: NMN vs. NR and Why It Matters

Route to NAD+

NMN and NR follow different absorption paths that may interact with gut microbiome composition, which differs across ancestral groups [3]. NR is absorbed intact through the intestinal epithelium and also converted to NAM by gut bacteria before systemic absorption. NMN was long thought to require conversion to NR before entering cells, but the discovery of the Slc12a8 transporter in intestinal epithelium suggested direct NMN uptake is possible in humans [3].

A 2023 pharmacokinetic study by Yi et al. (N=12) confirmed that oral NMN 300 mg produced measurable plasma NMN within 30 minutes post-dose, with peak NAD+ elevation at two to three hours [16]. No Hispanic-specific pharmacokinetic data exist.

Gut Microbiome as a Modifying Variable

The gut microbiome composition in Hispanic adults may differ from non-Hispanic white adults due to dietary patterns, antibiotic exposure history, and ancestry-linked microbial colonization [17]. Because intestinal bacteria convert NR and NMN to NAM before systemic absorption, a microbiome with higher nicotinamidase activity could blunt the fraction of intact NR or NMN reaching portal circulation. This remains a hypothesis; direct evidence linking Hispanic microbiome composition to NAD+ precursor pharmacokinetics has not been published.

Dietary and Lifestyle Factors in Hispanic Communities

Traditional Hispanic dietary patterns vary widely by country of origin, but common elements include corn-based foods processed with alkali (nixtamalization), which actually enhances niacin bioavailability compared to untreated corn [18]. This means some Hispanic patients may have a higher baseline dietary niacin intake than assumed from standard dietary assessment tools calibrated on U.S. General population norms.

Higher baseline niacin intake could influence the dose-response curve for NMN or NR supplementation. If the salvage pathway is already partially saturated by dietary NAM, incremental NAD+ gains from 250 mg NMN may be smaller than in a patient with dietary niacin deficiency.

Physical inactivity rates in Hispanic adults are higher than in non-Hispanic white adults according to CDC surveillance data [1]. Exercise is an independent activator of NAMPT expression in skeletal muscle, meaning a sedentary patient will have lower baseline NAMPT activity and potentially a different NMN response profile than an active comparator.

Practical Monitoring and Clinical Considerations

Baseline Assessment Before Starting NMN or NR

Before recommending NMN or NR to a Hispanic or Latino patient, the HealthRX medical team suggests the following baseline workup:

• Fasting glucose and HbA1c to classify glycemic status
• A lipid panel to assess metabolic syndrome components
• Whole blood NAD+ if available through a CLIA-certified lab
• A dietary assessment for habitual niacin intake

This panel takes about 10 minutes to order and gives the clinical team the data needed to interpret any downstream response.

Monitoring Response

Reassess whole blood NAD+ at 8 to 12 weeks. A response below 30% above baseline in a patient taking 500 mg/day NMN may indicate high CD38 or NNMT activity, pharmacogenomic NAMPT limitation, or non-adherence. Dose escalation to 1,000 mg/day is reasonable in that scenario, consistent with the safety range established by Martens et al. [8].

Drug Interactions Relevant to the Population

Metformin, used by approximately 57% of Hispanic adults with type 2 diabetes in U.S. Studies, has complex effects on mitochondrial function and NAD+ metabolism [19]. Some evidence suggests metformin may lower NAMPT expression modestly. The clinical significance of this interaction with concurrent NMN or NR use is not established. Clinicians should document concurrent metformin use and watch for additive hypoglycemia risk, though NMN and NR have not independently demonstrated hypoglycemic effects in published trials.

The Representation Problem in NAD+ Research

Who Gets Enrolled in Trials

A 2022 analysis of NAD+ precursor clinical trials registered on ClinicalTrials.gov found that Hispanic and Latino individuals were underrepresented in completed trials relative to their share of the U.S. Population [20]. This mirrors a broader pattern in metabolic research. The National Institutes of Health All of Us Research Program is actively recruiting a more diverse participant base, and future NMN or NR trials embedded in All of Us infrastructure may provide the first adequately powered ethnic subgroup data [21].

What Clinicians Should Tell Patients

Hispanic and Latino patients asking about NMN or NR deserve an honest explanation: the existing evidence base is encouraging but was not built around their population. The Yoshino 2021 trial showed real improvements in insulin sensitivity [7]. The Martens 2020 trial confirmed a 60% rise in blood NAD+ with NR 1,000 mg/day [8]. These findings are biologically applicable to Hispanic patients, but the magnitude of benefit, the optimal dose, and the long-term safety profile have not been confirmed in ethnicity-stratified studies.

The American Diabetes Association's 2024 Standards of Care note that individualized therapy considering social determinants, comorbidities, and patient-specific biology should guide all supplemental and pharmaceutical decisions in patients with diabetes [14]. NMN and NR fit within that individualization framework.

Summary of Evidence Levels by Clinical Question

| Clinical Question | Evidence Level | Source | |---|---|---| | Does NMN improve insulin sensitivity? | Moderate (single small RCT) | Yoshino et al. 2021 [7] | | Does NR raise blood NAD+? | Moderate (multiple RCTs) | Martens et al. 2020 [8] | | Are Hispanic patients specifically studied? | None | Gap in literature | | Do NAMPT variants affect NAD+ levels? | Moderate (population genomic studies) | PharmGKB, 1000 Genomes [10,11] | | Is higher dosing needed in metabolic disease? | Theoretical / mechanistic only | [5,6,12] |